Riskpilot← Back to searchSign inGet full accessBOTNGAARD BIOPROTIX AS
ASActiveOrg 915887872Kottengsveien 322, 7160 BjugnSlakting, bearbeiding og konservering av fisk og fiskevarer ellers · NACE 10209Est. 20150 employees
Revenue 2021
NOK 0
EBITDA margin
—
+78% vs 2020
Equity ratio
-7387.2%
Financial strength
Net profit 2021
NOK -21K
+78% vs 2020
| Revenue | NOK 0 | — |
| EBITDA | NOK -21K | +78% |
| Net profit | NOK -21K | +78% |
| Total assets | NOK 17K | -48% |
| Equity | NOK -1,3M | -2% |
| Employees | 0 | — |
Legal name
BOTNGAARD BIOPROTIX AS
Org number
915887872
Legal form
Aksjeselskap
NACE code
10209 · Slakting, bearbeiding og konservering av fisk og fiskevarer ellers
Founded
8. september 2015
Share capital
NOK 518 420
Employees
0
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Salg og produksjon av hjelpestoffer til fisk og dyrefor samt alt som står i naturlig forbindelse med dette.
Address
Kottengsveien 322, 7160 Bjugn
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 205 | 0 | 0 |
| Staff expenses | −1 192 | −578 | −0 | −0 | −0 |
| EBITDA | −2 640 | −506 | 90 | −96 | −21 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −2 640 | −506 | 90 | −96 | −21 |
| Net financials | −1 | −19 | −7 | −0 | −0 |
| Profit before tax | −2 641 | −524 | 83 | −96 | −21 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −2 641 | −524 | 83 | −96 | −21 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Total assets | 349 | 396 | 9 | 34 | 17 |
| Equity | −1 061 | −1 002 | −1 170 | −1 266 | −1 287 |
| Long-term debt | 0 | 632 | 782 | 1 107 | 1 114 |
| Short-term debt | 1 410 | 766 | 397 | 193 | 191 |
| Total debt | 1 410 | 1 398 | 1 179 | 1 300 | 1 305 |
EBITDA margin
-2146200.0%
This company
15.8%
Market median
-13583644% vs market
20172021
Equity ratio
-7387.2%
This company
38.2%
Market median
-19438% vs market
20172021
Return on equity
-2146600.0%
This company
18.4%
Market median
-11666404% vs market
20172021
Net profit margin
-2146600.0%
This company
8.1%
Market median
-26501335% vs market
20172021
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20172021
Debt / equity
1.01×
This company
0.62×
Market median
-63% vs market
20172021
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KB Chief Executive Officer | Chief Executive Officer | 2015 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 18.22% | 18.22% | 2022 | |
| Individual | 10.61% | 10.61% | 2022 | |
| Company | 9.64% | 9.64% | 2022 | |
| Company | 9.64% | 9.64% | 2022 | |
| Company | 9.64% | 9.64% | 2022 | |
| Company | 1.86% | 1.86% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BOTNGAARD BIOPROTIX AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Knut Botngård | Chief Executive Officer | 0 companies |
| Tor Langvold | Chairman | 0 companies |